```
=> b reg
FILE 'REGISTRY' ENTERED AT 18:13:37 ON 18 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   17 APR 2008  HIGHEST RN 1015473-28-5
DICTIONARY FILE UPDATES:  17 APR 2008  HIGHEST RN 1015473-28-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l11
L7              STR
```




```
VAR G1=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT   7
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E5 C  E1 N  AT   4
ECOUNT  IS E4 C  E2 N  AT   5

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   9

STEREO ATTRIBUTES: NONE
L9       159097 SEA FILE=REGISTRY ABB=ON  PLU=ON  (NC5 AND NC2NC2)/ES
L11         104 SEA FILE=REGISTRY SUB=L9 SSS FUL L7

100.0% PROCESSED   14121 ITERATIONS                          104 ANSWERS
SEARCH TIME: 00.00.01



=> b hcap
FILE 'HCAPLUS' ENTERED AT 18:13:44 ON 18 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 Apr 2008  VOL 148 ISS 17
```

FILE LAST UPDATED: 17 Apr 2008 (20080417/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitstr l14 tot

L14 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:818216 HCAPLUS
DN 145:241683
TI Pyridazine-based SCD-1 inhibitors for use in combination therapy to treat adverse weight gain associated with a drug therapy
IN Sadalapure, Kashinath; Abreo, Melwyn; Kondratenko, Mikhail; Harvey, Daniel; Hudson, Cindy; Li, Wenbao; Tu, Chi; Sun, Sengen; Holladay, Mark; Gschwend, Heinz; Kamboj, Rajender; Winther, Michael; Fraser, Robert; Chafeev, Mikhail; Fu, Jian-Min; Hou, Duanjie; Liu, Shifeng; Raina, Vandna; Seid Bagherzadeh, Mehran
PA Xenon Pharmaceuticals Inc., Can.
SO PCT Int. Appl., 149pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2006086445	A2	20060817	2006WO-US0004383	20060208
WO--2006086445	A3	20060914		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU--2006212761	A1	20060817	2006AU-000212761	20060208
CA-----2597067	A1	20060817	2006CA-002597067	20060208
EP-----1846035	A2	20071024	2006EP-000734555	20060208
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
MX---2007009592	A	20071016	2007MX-000009592	20070808
IN-2007CN03940	A	20071123	2007IN-CN0003940	20070910
PRAI 2005US-00651584P	P	20050209		
2006WO-US0004383	W	20060208		

OS MARPAT 145:241683
GI



I



II

AB This invention is directed to the use of SCD-1 inhibitors of the formula I [m, n = independently 1-3; W = a direct bond, NHCO and derivs., O, OCONH and derivs., CO, NHC(:NH)NH and derivs., etc.; V = CO, CS, CONH and derivs., etc.; G, J, L, M = independently N, CH and derivs., provided that at most 2 of G, J, L, and M are N; R2, R3 = independently alk(en)yl, aryl, etc.; each R5, R5a, R6, R6a, R7, R7a, R8, R8a = independently H, alkyl; or

L14 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
R5R5a] (e.g., II) in combination with other drug therapies, particularly drug therapies for diabetes, to treat the adverse wt. gain (no data). 30 Reaction schemes along with the assocd. general prepns., and 388 claimed compds. are given.
IT 842171-49-7, 1-Pentyl-3-[6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl]urea 842171-50-0, 1-Butyl-3-[6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl]urea 842171-52-2, 1-(2-Phenylethyl)-3-[6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl]urea 842171-54-4, 1-Benzyl-3-[6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl]urea 842171-56-6, 1-(4-Fluorobenzyl)-3-[6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl]urea
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SCD-1 inhibitor; use of pyridazine stearoyl-CoA desaturase-1 inhibitors in combination with other drug therapies for treating adverse weight gain)
IT 842171-49-7, 1-Pentyl-3-[6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl]urea
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SCD-1 inhibitor; use of pyridazine stearoyl-CoA desaturase-1 inhibitors in combination with other drug therapies for treating adverse weight gain)
RN 842171-49-7 HCAPLUS
CN Piperazine, 1-[5-[[(pentylamino)carbonyl]amino]-2-pyridinyl]-4-[2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:120715 HCAPLUS
DN 142:219311
TI Preparation of piperazinylpyridines as stearoyl-CoA desaturase inhibitors
IN Abreo, Melwyn; Harvey, Daniel F.; Gschwend, Heinz W.; Li, Wenbao; Tu, Chi; Kamboj, Rajender; Winther, Michael D.; Kodumuru, Vishnumurthy; Hudson, Cindy J.; Kondratenko, Mikhail A.; Liu, Shifeng; Raina, Vandna; Sviridov, Serguei; Zhang, Zaihui; Seid, Bagherzadeh Mehran; Sun, Shaoyi
PA Xenon Pharmaceuticals Inc., Can.
SO PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005011656	A2	20050210	2004WO-US0024657	20040729
WO--2005011656	A3	20050506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2004261267	A1	20050210	2004AU-000261267	20040729
CA-----2533900	A1	20050210	2004CA-002533900	20040729
EP-----1651606	A2	20060503	2004EP-000779655	20040729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR--2004012352	A	20060905	2004BR-000012352	20040729
CN-----1829691	A	20060906	2004CN-080021881	20040729
JP--2007500719	T	20070118	2006JP-000522095	20040729
US--20060199802	A1	20060907	2006US-000566193	20060130
MX--2006PA01203	A	20060920	2006MX-PA0001203	20060130
IN--2006CN00369	A	20070706	2006IN-CN00000369	20060130
NO--2006000972	A	20060502	2006NO-000000972	20060228
PRAI 2003US-00491116P	P	20030730		
2003US-00491118P	P	20030730		
2003US-00491340P	P	20030730		
2004WO-US0024657	W	20040729		

OS MARPAT 142:219311
GI



I

AB A method of inhibiting human stearoyl-CoA denaturase (hSCD) comprises contacting a source of hSCD with a title compound [I; W = O, NR1, CO, S, SO, SO2 NR1SO2, CONR1, NR1CONR1, etc.; V = CO, CS, CONR1, CO2, SO2, SO2NR1, CHR1i, etc.; m, n = 1-3; R1 = H, alkyl, hydroxyalkyl, cycloalkylalkyl, aralkyl; R2 = alkyl, alkenyl, hydroxyalkyl, hydroxyalkenyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, etc.; R3 = alkyl, alkenyl, hydroxyalkyl, hydroxyalkenyl, alkoxyalkyl, heteroaryl, etc.; R4-R6 = H, Br, F, Cl, Me, MeO, CF3, cyano, NO2, amino; R7-R11 = H, alkyl; R7R7a, R8R8a, R9R9a, R10R10a = O; 1 of R7, R7a, R10, R10a with 1 of R8, R8a, R9, R9a form an alkylene bridge; with provisos] (no data). Thus, pentyl isocyanate was added slowly to [4-(5-aminopyridin-2-yl)piperazin-1-yl]-(2-trifluoromethylphenyl)methanone (preparation given) in CH2Cl2 at 0° followed by stirring for 16 h at 25° to give 35% 1-pentyl-3-[6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-3-yl]urea.
IT 842171-49-7P 842171-50-0P 842171-52-2P

L14 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
842171-54-4P 842171-56-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compd.; prepn. of piperazinylpyridines as stearoyl-CoA desaturase inhibitors)
IT 842171-49-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of piperazinylpyridines as stearoyl-CoA desaturase inhibitors)
RN 842171-49-7 HCAPLUS
CN Piperazine, 1-[5-[[(pentylamino)carbonyl]amino]-2-pyridinyl]-4-[2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)



=> d bib abs hitrn fhitstr l15 tot

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:509793 HCAPLUS
DN 146:501044
TI Preparation of ureidopyrazoles as kinase inhibitors, particularly as p38 kinase inhibitors
IN Bastian, Jolie Anne; Blas De Blas, Jesus Andres; De Dios, Alfonso; Hudziak, Kevin John; Li, Tiechao; Lopez De Uralde-Garmendia, Beatriz; Mader, Mary Margaret; Myers, Michael Ray; Pobanz, Mark Andrew; Shih, Chuan; Zhong, Boyu
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 73pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2007053394	A1	20070510	2006WO-US0041644	20061025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI 2005US-00731604P	P	20051028		
2006EP-00038015l	A	20060602		
2006US-00821963P	P	20060810		

OS MARPAT 146:501044
GI



I



II

AB Title compds. [I; Z = (un)substituted 2,5-pyridinylene, 2,4-pyridinylene; X = (1-acylpiperidin-4-yl)oxy, (1-acylpiperidin-4-yl)amino, 2,5-(un)(di)substituted 1-acylpiperazin-4-yl; R1 = (un)substituted alkyl, cycloalkyl, trimethylsilyl; R2 = (un)substituted Ph, pyridinyl; and their pharmaceutically acceptable salts] were prepared as p38 kinase inhibitors. Thus, reacting [4-(5-amino-6-methylpyridin-2-yl)piperazin-1-yl](2,6-

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
tolyl)-2H-pyrazol-3-yl]-3-[2-methyl-6-[4-(2-methylbenzoyl)piperazin-1-yl]pyridin-3-yl]urea 936371-02-7P, 1-[6-[4-(2,6-Difluorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]-3-[5-(2-fluoro-1,1-dimethylethyl)-2-(p-tolyl)-2H-pyrazol-3-yl]urea 936371-28-7P, 1-[6-[4-(2,6-Difluorobenzoyl)piperazin-1-yl]-5-methylpyridin-3-yl]-3-[5-(2-fluoro-1,1-dimethylethyl)-2-(p-tolyl)-2H-pyrazol-3-yl]urea monomethanesulfonate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of ureidopyrazoles as p38 kinase inhibitors)
IT 936369-39-0P, 1-[5-tert-Butyl-2-(p-tolyl)-2H-pyrazol-3-yl]-3-[6-[4-(2,6-difluorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]urea
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of ureidopyrazoles as p38 kinase inhibitors)
RN 936369-39-0 HCAPLUS
CN Urea, N-[6-[4-(2,6-difluorobenzoyl)-1-piperazinyl]-2-methyl-3-pyridinyl]-N'-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
difluorophenyl)methanone (prepn. given) with [5-(tert-butyl)-2-(p-tolyl)-2H-pyrazol-3-yl]carbamic acid 2,2,2-trichloroethyl ester (prepn. given) in DMSO in the presence of DMAP and DIPEA, and acidulation with methanesulfonic acid (MeSO3H) gave II•MeSO3H. II•MeSO3H inhibited p38 kinase (IC50 = 22 nM) and p-MAPKAPK2 kinase (IC50 = 4.5 nM) and suppressed TNF-α in vitro (IC50 = 18 nM). I are useful for treating conditions resulting from excessive cytokine prodn. such as arthritis.
IT 936369-0P, 1-[5-tert-Butyl-2-(p-tolyl)-2H-pyrazol-3-yl]-3-[6-[4-(2,6-difluorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]urea
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of ureidopyrazoles as p38 kinase inhibitors)
IT 936370-43-3P, 1-[5-tert-Butyl-2-(p-tolyl)-2H-pyrazol-3-yl]-3-[6-[4-(2,6-difluorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]urea monomethanesulfonate
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of ureidopyrazoles as p38 kinase inhibitors)
IT 936371-27-6P, 1-[6-[4-(2,6-Difluorobenzoyl)piperazin-1-yl]-5-methylpyridin-3-yl]-3-[5-(2-fluoro-1,1-dimethylethyl)-2-(p-tolyl)-2H-pyrazol-3-yl]urea
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of ureidopyrazoles as p38 kinase inhibitors)
IT 936369-37-8P, 1-[6-[4-(2,6-Difluorobenzoyl)piperazin-1-yl]pyridin-3-yl]-3-[5-(1-methylcyclopropyl)-2-(p-tolyl)-2H-pyrazol-3-yl]urea
936369-40-3P 936369-44-7P 936369-46-9P
936369-48-1P 936369-50-5P 936369-52-7P
936369-54-9P 936369-56-1P 936369-58-3P
936369-60-7P 936369-62-9P 936369-64-1P
936369-66-3P 936369-68-5P 936369-70-9P
936369-72-1P 936369-74-3P 936369-76-5P
936369-78-7P 936369-80-1P 936369-82-3P
936369-84-5P 936369-86-7P 936369-88-9P
936369-90-3P 936370-00-2P 936370-02-4P
936370-08-0P 936370-10-4P 936370-18-2P
936370-20-6P 936370-21-7P, 1-[5-tert-Butyl-2-(p-tolyl)-2H-pyrazol-3-yl]-3-[6-[4-(2,6-difluorobenzoyl)piperazin-1-yl]pyridin-3-yl]urea 936370-22-8P, 1-[5-tert-Butyl-2-(p-tolyl)-2H-pyrazol-3-yl]-3-[6-[4-(2,6-dichlorobenzoyl)piperazin-1-yl]pyridin-3-yl]urea
936370-36-4P, 1-[5-tert-Butyl-2-(p-tolyl)-2H-pyrazol-3-yl]-3-[6-[4-(2,6-difluorobenzoyl)piperazin-1-yl]-5-methylpyridin-3-yl]urea
936370-39-7P, 1-[5-tert-Butyl-2-(p-tolyl)-2H-pyrazol-3-yl]-3-[5-chloro-6-[4-(2,6-difluorobenzoyl)piperazin-1-yl]pyridin-3-yl]urea
936370-42-2P, 1-[6-[4-(2,6-Difluorobenzoyl)piperazin-1-yl]pyridin-3-yl]-3-[2-(p-tolyl)-5-(trimethylsilanyl)-2H-pyrazol-3-yl]urea
936370-57-9P, 1-[5-tert-Butyl-2-(6-methylpyridin-3-yl)-2H-pyrazol-3-yl]-3-[6-[4-(2-chlorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]urea
936370-58-0P, 1-[5-tert-Butyl-2-(6-methylpyridin-3-yl)-2H-pyrazol-3-yl]-3-[6-[4-(2-fluorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]urea
936370-60-4P, 1-[6-[4-(2-Chlorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]-3-[2-(6-methylpyridin-3-yl)-5-(1-trifluoromethylcyclopropyl)-2H-pyrazol-3-yl]urea 936370-61-5P, 1-[6-[4-(2-Fluorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]-3-[2-(6-methylpyridin-3-yl)-5-(1-trifluoromethylcyclopropyl)-2H-pyrazol-3-yl]urea
936370-62-6P, 1-[6-[4-(2,6-Difluorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]-3-[2-(6-methylpyridin-3-yl)-5-(1-trifluoromethylcyclopropyl)-2H-pyrazol-3-yl]urea 936370-73-9P, 1-[5-tert-Butyl-2-(p-tolyl)-2H-pyrazol-3-yl]-3-[6-[4-(2,4-difluorobenzoyl)piperazin-1-yl]pyridin-3-yl]urea 936370-81-9P
936370-83-1P 936370-85-3P 936370-89-7P
936370-94-4P 936370-95-5P 936370-97-7P
936370-98-8P 936370-99-9P 936371-00-5P, 1-[6-[4-(2,6-Difluorobenzoyl)piperazin-1-yl]-2-methylpyridin-3-yl]-3-[5-(2-fluoro-1-fluoromethyl-1-methylethyl)-2-(p-tolyl)-2H-pyrazol-3-yl]urea
936371-01-6P, 1-[5-(2-Fluoro-1-fluoromethyl-1-methylethyl)-2-(p-

L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:818216 HCAPLUS
DN 145:241683
TI Pyridazine-based SCD-1 inhibitors for use in combination therapy to treat adverse weight gain associated with a drug therapy
IN Sadalapure, Kashinath; Abreo, Melwyn; Kondratenko, Mikhail; Harvey, Daniel; Hudson, Cindy; Li, Wenbao; Tu, Chi; Sun, Sengen; Holladay, Mark; Gschwend, Heinz; Kamboj, Rajender; Winther, Michael; Fraser, Robert; Chafeev, Mikhail; Fu, Jian-Min; Hou, Duanjie; Liu, Shifeng; Raina, Vandna; Seid Bagherzadeh, Mehran
PA Xenon Pharmaceuticals Inc., Can.
SO PCT Int. Appl., 149pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2006086445	A2	20060817	2006WO-US0004383	20060208
WO--2006086445	A3	20060914		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU--2006212761	A1	20060817	2006AU-000212761	20060208
CA-----2597067	A1	20060817	2006CA-002597067	20060208
EP-----1846035	A2	20071024	2006EP-000734555	20060208
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
MX---200709592	A	20071016	2007MX-000009592	20070808
IN-2007CN03940	A	20071123	2007IN-CN0003940	20070910
PRAI 2005US-00651584P	P	20050209		
2006WO-US0004383	W	20060208		

OS MARPAT 145:241683
GI

I

II

AB This invention is directed to the use of SCD-1 inhibitors of the formula I [m, n = independently 1-3; W = a direct bond, NHCO and derivs., O, OCONH and derivs., CO, NHC(:NH)NH and derivs., etc.; V = CO, CS, CONH and derivs., etc.; G, J, L, M = independently N, CH and derivs., provided that at most 2 of G, J, L, and M are N; R2, R3 = independently alk(en)yl, aryl, etc.; each R5, R5a, R6, R6a, R7, R7a, R8, R8a = independently H, alkyl; or R5R5a] (e.g., II) in combination with other drug therapies, particularly drug therapies for diabetes, to treat the adverse weight gain (no data). 30 Reaction schemes along with the associated general prepns., and 388 claimed compds. are given.

L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 842171-03-3, 1-(3-Methylbutyl)-3-[5-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-2-yl]urea 842171-04-4, 1-Pentyl-3-[5-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-2-yl]urea 842171-05-5, 1-Butyl-3-[5-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-2-yl]urea 842171-06-6, 1-[3-(4-Fluorophenyl)propyl]-3-[5-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-2-yl]urea 842171-07-7, 1-Phenethyl-3-[5-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-2-yl]urea 842171-08-8, 1-Benzyl-3-[5-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-2-yl]urea
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SCD-1 inhibitor; use of pyridazine stearoyl-CoA desaturase-1 inhibitors in combination with other drug therapies for treating adverse weight gain)
IT 842171-03-3, 1-(3-Methylbutyl)-3-[5-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridin-2-yl]urea
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SCD-1 inhibitor; use of pyridazine stearoyl-CoA desaturase-1 inhibitors in combination with other drug therapies for treating adverse weight gain)
RN 842171-03-3 HCAPLUS
CN Piperazine, 1-[6-[[[(3-methylbutyl)amino]carbonyl]amino]-3-pyridinyl]-4-[2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
F, Cl, Me, MeO, CF3, cyano, NO2, amino; R7-R11 = H, alkyl; R7R7a, R8R8a, R9R9a, R10R10a = O; 1 of R7, R7a, R10, R10a with 1 of R8, R8a, R9, R9a form an alkylene bridge; with provisos] (no data). Thus, trifluoromethanesulfonic acid 6-(3-phenylpropylcarbamoyl)pyridin-3-yl ester (prepn. given) and piperazin-1-yl-(2-trifluoromethylphenyl)methanone (prepn. given) in PhMe were added to a mixt. of Cs2CO3, Pd(OAc)2, and BINAP followed by heating at 100° for 26 h to give 13% 5-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridine-2-carboxylic acid (3-phenylpropyl)amide.
IT 842171-03-3P 842171-04-4P 842171-05-5P 842171-06-6P 842171-07-7P 842171-08-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of piperazinylpyridines as inhibitors of human stearoyl CoA desaturase)
IT 842171-03-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of piperazinylpyridines as inhibitors of human stearoyl CoA desaturase)
RN 842171-03-3 HCAPLUS
CN Piperazine, 1-[6-[[[(3-methylbutyl)amino]carbonyl]amino]-3-pyridinyl]-4-[2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:120713 HCAPLUS
DN 142:219309
TI Preparation of piperazinylpyridines as inhibitors of human stearoyl CoA desaturase (hSCD).
IN Abrec, Melwyn; Harvey, Daniel F.; Kondratenko, Mikhail A.; Li, Wenbao; Kamboj, Rajender; Kodumuru, Vishnumurthy; Winther, Michael D.; Gschwend, Heinz W.; Chakka, Nagasree; Liu, Shifeng; Sviridov, Serguei; Sun, Shaoyi
PA Xenon Pharmaceuticals Inc., Can.
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2005011654	A2	20050210	2004WO-US0024542	20040729
	WO--2005011654	A3	20050414		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2004261250	A1	20050210	2004AU-000261250	20040729
	CA-----2533898	A1	20050210	2004CA-002533898	20040729
	EP-----1651605	A2	20060503	2004EP-000779556	20040729
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN-----1829690	A	20060906	2004CN-080021951	20040729
	BR--2004013059	A	20061031	2004BR-000013059	20040729
	JP--2007500716	T	20070118	2006JP-000522073	20040729
	IN-2006CN00356	A	20070706	2006IN-CN0000356	20060127
	MX-2006PA01202	A	20060831	2006MX-PA0001202	20060130
	US-20060293308	A1	20061228	2006US-000566857	20060130
	IN-2006CN00368	A	20070706	2006IN-CN0000368	20060130
	NO--2006000973	A	20060427	2006NO-000000973	20060228
PRAI	2003US-00491140P	P	20030729		
	2003US-00491080P	P	20030730		
	2003US-00491116P	P	20030730		
	2003US-00491141P	P	20030730		
	2003US-00491322P	P	20030730		
	2003US-00491095P	P	20030730		
	2004WO-US0024542	W	20040729		

OS CASREACT 142:219309; MARPAT 142:219309
GI



I

AB A method of inhibiting human stearoyl-CoA denaturase (hSCD) comprises contacting a source of hSCD with a title compound [I; W = O, NR1, CO, S, SO, SO2 NR1SO2, CONR1, NR1CONR1, etc.; V = CO, CS, CONR1, CO2, SO2, SO2NR1, CHR11, etc.; m, n = 1-3; R1 = H, alkyl, hydroxyalkyl, cycloalkylalkyl, aralkyl; R2 = alkyl, alkenyl, hydroxyalkyl, hydroxyalkenyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, etc.; R3 = alkyl, alkenyl, hydroxyalkyl, hydroxyalkenyl, alkoxyalkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, etc.; R4-R6 = H, Br,

```
=> d his

     (FILE 'HOME' ENTERED AT 18:05:29 ON 18 APR 2008)

     FILE 'HCAPLUS' ENTERED AT 18:05:37 ON 18 APR 2008
L1            1 US20060199802/PN

     FILE 'REGISTRY' ENTERED AT 18:06:05 ON 18 APR 2008

     FILE 'HCAPLUS' ENTERED AT 18:06:05 ON 18 APR 2008
L2              TRA L1 1- RN :       50 TERMS

     FILE 'REGISTRY' ENTERED AT 18:06:05 ON 18 APR 2008
L3           50 SEA L2
L4           39 L3 AND NC2NC2/ES
L5           37 L4 AND 46.156.30/RID
L6           32 L5 AND (C6 OR C6-C6)/ES
L7              STR
L8            0 L7
L9       159097 (NC5 AND NC2NC2)/ES
L10           9 L7 SAM SUB=L9
L11         104 L7 FULL SUB=L9
                SAV TEM J193C1GII/A L11
L12           5 L11 AND L3
L13          99 L11 NOT L12

     FILE 'HCAPLUS' ENTERED AT 18:11:53 ON 18 APR 2008
L14           2 L12
L15           3 L13

     FILE 'HCAOLD' ENTERED AT 18:12:27 ON 18 APR 2008
L16           0 L12
L17           0 L13

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 18:12:35 ON 18 APR 2008
L18           0 L12
L19           0 L13

     FILE 'REGISTRY' ENTERED AT 18:13:37 ON 18 APR 2008

     FILE 'HCAPLUS' ENTERED AT 18:13:44 ON 18 APR 2008

=>
```